RxDoctor Payments Data

Patricia Schrader, NP

Adult Health · Saint Louis, MONPI 1689022089

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 47.1% of the total. Among adult health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,545in general payments, 2019–2025

Across 363 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Bristol Myers Squibb$640
  • Lilly USA, LLC$619
  • Pfizer$409
  • Biogen$361
  • UCB, Inc.$340
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$8,45799%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,545 in reported general payments places this provider in the 90th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$167,696
Medicare patients
131
Services billed
23,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm79$60,509
Aimovig AutoinjectorErenumab-Aooe68$50,590
UbrelvyUbrogepant27$41,056
Ajovy AutoinjectorFremanezumab-Vfrm33$25,646
Nurtec OdtRimegepant Sulfate16$23,835
QuliptaAtogepant14$14,953
Gabapentin60$3,180
Memantine Hcl48$1,910
Carbidopa-LevodopaCarbidopa/Levodopa23$1,333
Naratriptan Hcl32$768
RizatriptanRizatriptan Benzoate32$758
Duloxetine Hcl26$745
Sumatriptan Succinate75$717
Baclofen55$708
Tizanidine Hcl47$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$4,023$56,00841 claims
PfizerNurtec Odt$409$23,83516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →